Helius Medical Technologies, Inc. Reports First Quarter 2022 Financial Results and Provides Update on U.S. Commercial Launch of PoNS®
12. Mai 2022 06:50 ET
|
Helius Medical Technologies, Inc.
-- Company to host call at 9:00am today with CEO, CFO, CMO and VP Sales & Marketing -- NEWTOWN, Pa., May 12, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius”...
Helius Medical Technologies, Inc. to Release First Quarter 2022 Financial Results on May 12, 2022
03. Mai 2022 07:05 ET
|
Helius Medical Technologies, Inc.
NEWTOWN, Pa., May 03, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (TSX: HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today...
Helius Medical Technologies, Inc. Fulfills First U.S. Prescriptions for PoNS®
27. April 2022 07:05 ET
|
Helius Medical Technologies, Inc.
-- First patients have purchased PoNS devices to initiate PoNS Therapy ---- Nineteen PoNS device prescriptions have been written in the U.S. since recent commercial launch -- NEWTOWN, Pa., April 27,...
Helius Medical Technologies, Inc. Introduces Device in U.S. To Help Multiple Sclerosis Patients Improve Walking Ability
26. April 2022 07:05 ET
|
Helius Medical Technologies, Inc.
-- Breakthrough technology for MS patients helps patients with gait deficit -- Portable Neuromodulation Stimulator (PoNS®) is an innovative non-surgical medical device that includes a controller and...
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results
14. März 2022 16:05 ET
|
Helius Medical Technologies, Inc.
NEWTOWN, Pa., March 14, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported...
Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17. Februar 2022 17:20 ET
|
Helius Medical Technologies, Inc.
NEWTOWN, Pa., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced...
Helius Medical Technologies, Inc. Provides Corporate Update
26. Januar 2022 16:30 ET
|
Helius Medical Technologies, Inc.
-- Fourth Quarter 2021 Revenue Projected to Range from $250,000 to $260,000 -- -- Unaudited Year End Cash Balance of $11 million -- -- Continued Progress Toward U.S. Commercial Launch of...
Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20. Dezember 2021 17:00 ET
|
Helius Medical Technologies, Inc.
NEWTOWN, Pa., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced...
Helius Medical Technologies, Inc. Partners with the Medical University of South Carolina in Pilot Trial on Stroke
17. Dezember 2021 07:05 ET
|
Helius Medical Technologies, Inc.
-- PoNS ® to be used in study of cranial-nerve non-invasive neuromodulation and dynamic gait balance in stroke patients -- -- Collaboration will inform Helius’s registrational program in stroke -- ...
Helius Medical Technologies, Inc. Announces Issuance of U.S. Patent for Wireless PoNS®
14. Dezember 2021 07:05 ET
|
Helius Medical Technologies, Inc.
NEWTOWN, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (Helius or the Company), a neurotech company focused on neurological wellness, today announced that...